UK Markets closed

Immatics Announces First Quarter 2022 Financial Results and Business Update

  • Oops!
    Something went wrong.
    Please try again later.
·14-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Immatics N.V.
Immatics N.V.
  • ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2nd-generation IMA203CD8 granted

  • Phase 1 clinical trial initiated with the first T cell engaging receptor TCER® IMA401 targeting MAGEA4/8 for patients with recurrent and/or refractory solid tumors

  • New multi-program collaboration with Bristol Myers Squibb to develop allogeneic TCR-T/CAR-T programs; agreement includes $60 million upfront payment to Immatics and up to $700 million per program in milestone payments as well as tiered royalties

  • Bristol Myers Squibb and Immatics are also including an additional target to their autologous TCR-T collaboration signed in 2019, Immatics to receive an upfront payment of $20 million and eligibility for milestone payments and royalties

  • Cash and cash equivalents as well as other financial assets of $280.5 million1 (€252.7 million) as of March 31, 2022. With the upfront payment from the new collaboration agreement with Bristol Myers Squibb, cash reach into 2H 2024


Tuebingen, Germany and Houston, Texas, June 2, 2022Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended March 31, 2022.

Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics commented, “Immatics has continued to build positive momentum in the first quarter of 2022. We have started treatment in two of three Phase 1b cohorts advancing our IMA203 TCR-T studies targeting PRAME. We have reached a key milestone by entering the first-in-human trial with our first TCR Bispecifics candidate directed against MAGEA4/A8 and have set the stage for further advancing our TCER® pipeline. We have also further strengthened our pipeline portfolio to address the needs of cancer patients by joining forces with Bristol Myers Squibb to develop multiple off-the-shelf TCR-T and/or CAR-T programs based on our allogeneic gamma-delta cell therapy platform ACTallo®.”

First Quarter 2022 and Subsequent Company Progress

Adoptive Cell Therapy Programs

  • ACTallo® and Autologous TCR-T – Immatics entered into a strategic multi-program collaboration with Bristol Myers Squibb to develop allogeneic TCR-T/CAR-T programs combining Immatics’ proprietary gamma-delta T cell-derived, allogeneic Adoptive Cell Therapy (ACT) platform ACTallo®, with a suite of next-generation technologies developed by Bristol Myers Squibb. Immatics will receive an upfront payment of $60 million and is eligible for up to $700 million per Bristol Myers Squibb program through development, regulatory and commercial milestone payments and tiered royalty payments up to low double-digit percentages on net sales. The new collaboration covers development and commercialization of two programs for Bristol Myers Squibb. Both companies have an option to develop up to four additional programs each. In addition, Bristol Myers Squibb and Immatics will expand their autologous T cell receptor-based therapy (TCR-T) collaboration signed in 2019 by including one additional TCR-T target discovered by Immatics. Immatics will receive a payment of $20 million and eligibility for milestone payments as well as tiered royalties.

  • ACTengine® IMA203 (PRAME) – Update on Phase 1b expansion cohorts:

    • Cohort A – IMA203 as monotherapy: First patient treated at provisional Recommended Phase 2 Dose (RP2D) in March

    • Cohort B – IMA203 in combination with an immune checkpoint inhibitor: First patient treated at RP2D in May

    • Cohort C – IMA203CD8, a 2nd generation monotherapy where IMA203 is co-transduced with a CD8 co-receptor: IND granted by FDA, patient enrollment planned for Q2 2022

The next data read-out for the IMA203 monotherapy cohort is planned for 2H 2022. An initial data read-out for the IMA203/immune checkpoint inhibitor combination therapy cohort and the IMA203CD8 cohort is planned for YE2022.

  • ACTengine® IMA201 (MAGEA4/A8) – Dose escalation is ongoing, target dose level to commence.

  • ACTengine® IMA202 (MAGEA1) – A preliminary interim analysis from 16 patients treated in the dose escalation cohort demonstrated a favorable tolerability profile for IMA202. Signs of clinical and biological activity were observed, but were not reaching the threshold of objective responses as per RECIST1.1. Treatment-emergent adverse events for IMA202 were transient and manageable. No dose-limiting toxicities or signs of auto-immune toxicities were observed. 11 out of 16 patients (69%) showed disease control and 5 out of 16 patients (31%) showed tumor shrinkage. Maximum change of target lesion was minus 35%. Following final evaluation, Immatics plans to present the full data set at a later timepoint. Immatics management has decided not to further progress the IMA202 program into Phase 1b dose expansion and is evaluating development options and partnering opportunities for the program and the target MAGEA1.

TCR Bispecifics Programs

  • TCER® IMA401 (MAGEA4/8) Immatics initiated a Phase 1 clinical trial with its T cell engaging receptor (TCER®) IMA401 for patients with recurrent and/or refractory solid tumors. IMA401 is the most advanced TCER® candidate and targets an HLA-A*02-presented peptide derived from both MAGEA4 and/or MAGEA8. TCER® IMA401 is being developed in collaboration with Bristol Myers Squibb. Immatics is responsible for conducting the Phase 1 clinical trial with approximately 50 patients at up to 15 centers in Germany.

  • TCER® IMA402 (PRAME) – Manufacturing of the clinical batch is on track for the 2H 2022 and initiation of the Phase 1 trial is planned in 2023.

Corporate Developments

Board of Directors Update

  • Nancy Valente, M.D., was appointed to Immatics’ Board of Directors in March 2022 and will be nominated for election at Immatics’ Annual General Meeting in June 2022. She brings over 20 years of experience in oncology and hematology drug development. Additional information on all members of Immatics’ Board of Directors can be found on the Immatics website.

First Quarter 2022 Financial Results

Cash Position: Cash and cash equivalents as well as other financial assets total €252.7 million ($280.5 million1) as of March 31, 2022 compared to €145.1 million ($161.1 million1) as of December 31, 2021. The increase is mainly due to the receipt of the upfront payment in connection with the collaboration agreement with Bristol Myers Squibb on IMA401, partly offset by the financing of our ongoing research and development activities. This does not include $60 million cash to be received from the collaboration agreement signed with Bristol Myers Squibb in May 2022 or the $20 million cash to be received as a result of Bristol Myers Squibb’s decision to add one additional autologous TCR-T target as part of a 2019 collaboration agreement. With the addition of these upfront payments, the Company projects a cash runway into 2H 2024.

Revenue: Total revenue, consisting of revenue from collaboration agreements, was €102.9 million ($114.2 million1) for the three months ended March 31, 2022, compared to €7.4 million ($8.2 million1) for the three months ended March 31, 2021. The increase is mainly related to the recognition of revenue for the license portion of the collaboration agreement with Bristol Myers Squibb on IMA401.

Research and Development Expenses: R&D expenses were €25.1 million ($27.9 million1) for the three months ended March 31, 2022, compared to €23.0 million ($25.5 million1) for the three months ended March 31, 2021.

General and Administrative Expenses: G&A expenses were €9.3 million ($10.3 million1) for the three months ended March 31, 2022, compared to €8.4 million ($9.3 million1) for the three months ended March 31, 2021.

Net Income/Loss: Net income was €85.7 million ($95.1 million1) for the three months ended March 31, 2022, compared to a net loss of €22.8 million ($25.3 million1) for the three months ended March 31, 2021. The increase mainly resulted from a one-time revenue in connection with the partial recognition of the upfront payment from the collaboration with Bristol Myers Squibb on IMA401.

Full financial statements can be found in the current report on Form 6-K filed with the Securities and Exchange Commission (SEC) and published on the SEC website under www.sec.gov.

1 All amounts translated using the exchange rate published by the European Central Bank in effect as of March 31, 2022 (1 EUR = 1.1101 USD).

Upcoming Investor Conferences

  • Jefferies Global Healthcare Conference (in-person) New York, NY – June 8-10, 2022

  • Jefferies London Healthcare Conference, London, U.K. – November 15-17, 2022

To see the full list of events and presentations, visit www.investors.immatics.com/events-presentations.

- END -

About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

For regular updates about Immatics, visit www.immatics.com. You can also follow us on Instagram, Twitter and LinkedIn.

Forward-Looking Statements:
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.

For more information, please contact:

Media and Investor Relations Contact

Jacob Verghese or Eva Mulder

Trophic Communications

Phone: +49 89 2070 89831 or +31 6 52 33 1579

immatics@trophic.eu


Immatics N.V.

 

Anja Heuer

Jordan Silverstein

Director, Corporate Communications

Head of Strategy

Phone: +49 89 540415-606

Phone: +1 281 810 7545

media@immatics.com

InvestorRelations@immatics.com

Unaudited Condensed Consolidated Statement of Financial Position of Immatics N.V.

 

As of

 

March 31,
2022

December 31,
2021

 

 

 

 

(Euros in thousands)

Assets

 

 

Current assets

 

 

Cash and cash equivalents

247,316

132,994

Other financial assets

5,428

12,123

Accounts receivable

742

682

Other current assets

6,432

6,408

 

 

 

Total current assets

259,918

152,207

Non-current assets

 

 

Property, plant and equipment

10,801

10,506

Intangible assets

1,287

1,315

Right-of-use assets

9,297

9,982

Other non-current assets

879

636

 

 

 

Total non-current assets

22,264

22,439

 

 

 

Total assets

282,182

174,646

 

 

 

Liabilities and shareholders’ equity

 

 

Current liabilities

 

 

Provisions

1,405

51

Accounts payable

13,304

11,624

Deferred revenue

61,444

50,402

Other financial liabilities

11,331

27,859

Lease liabilities

2,770

2,711

Other current liabilities

1,600

2,501

 

 

 

Total current liabilities

91,854

95,148

Non-current liabilities

 

 

Deferred revenue

67,787

48,225

Lease liabilities

6,491

7,142

Other non-current liabilities

63

68

 

 

 

Total non-current liabilities

74,341

55,435

Shareholders’ equity

 

 

Share capital

629

629

Share premium

570,894

565,192

Accumulated deficit

(452,151)

(537,813)

Other reserves

(3,385)

(3,945)

 

 

 

Total shareholders’ equity

115,987

24,063

 

 

 

Total liabilities and shareholders’ equity

282,182

174,646

Unaudited Condensed Consolidated Statement of Income/(Loss) of Immatics N.V.

 

 

 

 

 

Three months ended March 31,

 

 

2022

2021

 

 

(Euros in thousands, except share and per
share data)

 

 

 

 

 

Revenue from collaboration agreements

102,907

7,403

 

Research and development expenses

(25,144)

(23,049)

 

General and administrative expenses

(9,278)

(8,431)

 

Other income

7

239

 

 

 

 

 

Operating result

68,492

(23,838)

 

Financial income

1,759

3,464

 

Financial expenses

(1,117)

(1,224)

 

Change in fair value of warrant liabilities

16,528

(1,215)

 

 

 

 

 

Financial result

17,170

1,025

 

 

 

 

 

Income/(loss) before taxes

85,662

(22,813)

 

Taxes on income

 

 

 

 

 

 

 

 

 

 

Net income/(loss)

85,662

(22,813)

 

 

 

 

 

Net income/(loss) per share:

 

 

 

Basic

1.36

(0.36)

 

Diluted

1.35

(0.36)

 

Weighted average shares outstanding:

 

 

 

Basic

62,927,205

62,908,791

 

Diluted

63,402,023

62,908,791

 

Unaudited Condensed Consolidated Statement of Comprehensive Income/(Loss) of Immatics N.V.

 

Three months ended March 31,

 

2022



2021

 

 

 

 

(Euros in thousands)

Net income/(loss)

85,662

(22,813)

Other comprehensive income/(loss)

 

 

Items that may be reclassified subsequently to profit or loss, net of tax

 

 

Currency translation differences from foreign operations

560

2,725

 

 

 

Total comprehensive income/(loss) for the period

86,222

(20,088)

 

 

 

Unaudited Condensed Consolidated Statement of Cash Flows of Immatics N.V.

 

Three months ended March 31,

 

2022

2021

 

 

 

 

(Euros in thousands)

Cash flows from operating activities

 

 

Income/(loss) before taxation

85,662

(22,813)

Adjustments for:

 

 

Interest income

(6)

(49)

Depreciation and amortization

1,636

1,094

Interest expense

162

70

Equity settled share-based payment

5,702

8,304

Net foreign exchange differences

126

318

Change in fair value of warrant liabilities

(16,528)

1,215

Changes in:

 

 

(Increase)/decrease in accounts receivable

(61)

676

(Increase)/decrease in other assets

(235)

1,207

Increase/(decrease) in accounts payable and other current liabilities

32,800

(6,645)

Interest received

6

36

Interest paid

(162)

(70)

 

 

 

Net cash (used in)/provided by operating activities

109,102

(16,657)

 

 

 

Cash flows from investing activities

 

 

Payments for property, plant and equipment

(1,156)

(565)

Cash paid for investments classified in Other financial assets

Cash received from maturity of investments classified in Other financial assets

6,993

3,126

Payments for intangible assets

(2)

(6)

Proceeds from disposal of property, plant and equipment

1

4

 

 

 

Net cash (used in)/provided by investing activities

5,836

2,559

 

 

 

Cash flows from financing activities

 

 

Proceeds from issuance of shares to equity holders of the parent

Payments for leases

(689)

(482)

 

 

 

Net cash (used in)/provided by financing activities

(689)

(482)

 

 

 

Net increase/(decrease) in cash and cash equivalents

114,249

(14,580)

 

 

 

Cash and cash equivalents at beginning of period

132,994

207,530

 

 

 

Effects of exchange rate changes on cash and cash equivalents

73

2,383

 

 

 

Cash and cash equivalents at end of period

247,316

195,333

 

 

 

Unaudited Condensed Consolidated Statement of Changes in Shareholders’ equity of Immatics N.V.

(Euros in thousands)

Share
capital

Share
premium

Accumulated
deficit

Other
reserves

Total
share-
holders’
equity

Balance as of January 1, 2021

629

538,695

(444,478)

(7,459)

87,387

Other comprehensive income

2,725

2,725

Net loss

(22,813)

(22,813)

Comprehensive income/(loss) for the year

—  

—  

(22,813)

2,725

(20,088)

Equity-settled share-based compensation

8,304

8,304

 

 

 

 

 

 

Balance as of March 31, 2021

629

546,999

(467,291)

(4,734)

75,603

 

 

 

 

 

 

Balance as of January 1, 2022

629

565,192

(537,813)

(3,945)

24,063

Other comprehensive income

560

560

Net loss

85,662

85,662

Comprehensive income/(loss) for the year

—  

—  

85,662

560

86,222

Equity-settled share-based compensation

5,702

5,702

Share options exercised

 

 

 

 

 

 

Balance as of March 31, 2022

629

570,894

(452,151)

(3,385)

115,987

 

 

 

 

 

 

 

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting